VYNE Therapeutics Inc [NASDAQ: VYNE] closed the trading session at $271340.0 on 2025-06-25. The day’s price range saw the stock hit a low of $1.08, while the highest price level was $1.59.
The stocks have a year to date performance of -24.73 percent and weekly performance of 49.14 percent. The stock has been moved at -42.68 percent over the last six months. The stock has performed 31.73 percent around the most recent 30 days and changed -21.26 percent over the most recent 3-months.
If compared to the average trading volume of 271.34K shares, VYNE reached to a volume of 7462850 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about VYNE Therapeutics Inc [VYNE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VYNE shares is $6.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VYNE stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BTIG Research have made an estimate for VYNE Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 18, 2024. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on December 06, 2021, representing the official price target for VYNE Therapeutics Inc stock.
The Price to Book ratio for the last quarter was 0.50, with the Price to Cash per share for the same quarter was set at 3.02.
VYNE stock trade performance evaluation
VYNE Therapeutics Inc [VYNE] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 49.14. With this latest performance, VYNE shares gained by 31.73% in over the last four-week period, additionally sinking by -42.68% over the last 6 months – not to mention a drop of -59.10% in the past year of trading.
VYNE Therapeutics Inc [VYNE]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and VYNE Therapeutics Inc [VYNE] shares currently have an operating margin of -7513.06%. VYNE Therapeutics Inc’s Net Margin is presently recorded at -6972.73%.
Return on Equity for this stock declined to -56.95%, with Return on Assets sitting at -56.95%.
Earnings per share (EPS) analysis for VYNE Therapeutics Inc [VYNE] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VYNE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for VYNE Therapeutics Inc go to 11.71%.
VYNE Therapeutics Inc [VYNE]: Institutional Ownership
There are presently around $47.62%, or 51.96% of VYNE stock, in the hands of institutional investors. The top three institutional holders of VYNE stocks are: EVENTIDE ASSET MANAGEMENT, LLC with ownership of 1.39 million shares, which is approximately 3.2742%. CORMORANT ASSET MANAGEMENT, LP, holding 1.39 million shares of the stock with an approximate value of $$2.75 million in VYNE stocks shares; and CORMORANT ASSET MANAGEMENT, LP, currently with $$2.39 million in VYNE stock with ownership which is approximately 2.8438%.
